Non-specific delayed-type hypersensitivity response to treat herpes simplex virus infection
AssigneesSquarex, LLC, The Board of Trustees of the University of Arkansa
InventorsHugh McTavish, Thomas Dag Horn, Sandra Marchese Johnson
Life of this patent
Estimating the term…
Abstract
A method is presented for treating herpes simplex virus (HSV) infection comprising: (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection.
Claims28
A method of treating herpes simplex virus (HSV) infection comprising:
- (a) locally administering a substance that induces a delayed type hypersensitivity (DTH) response to a patient at a site of an HSV lesion to induce a DTH response at the site of the lesion during one or more outbreaks of the HSV infection;
- wherein the method reduces the frequency or severity of subsequent HSV outbreaks in the patient.
(canceled)
(canceled)
16-17. (canceled)
20-21. (canceled)
A medical use of a substance capable of inducing a delayed-type hypersensitivity (DTH) response in humans to prepare a medicament effective to reduce the frequency or severity of subsequent herpes simplex virus (HSV) outbreaks in a patient with HSV infection.
The medical use of claim 17 wherein the substance is a topical contact sensitizer capable of inducing a DTH response in humans when administered topically.
The medical use of claim 17 wherein the substance is an antigen capable of inducing a DTH response in humans when injected intradermally.
Dependencies are inferred from the claim text.